¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer

Anticancer Res. 2016 Jan;36(1):367-73.

Abstract

Background/aim: The purpose of the present study was to improve the diagnostic precision of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) after neoadjuvant chemotherapy (NAC) in patients with advanced esophageal cancer.

Patients and methods: Thirty patients underwent FDG-PET/CT before and after NAC. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were measured. Patients were divided into two pathological response groups: "responders" (grades 1b-3) or "non-responders" (grades 0-1a).

Results: Overall, 11 patients were responders. Significant differences were present for the post-NAC SUVmax (p=0.070), %decrease in SUVmax (p=0.017), post-NAC MTV (p=0.014), and %decrease in MTV (p=0.003).

Conclusion: Receiver operating characteristic curve analysis showed that the %decrease in MTV of the primary tumor was the best indicator of response to NAC. We are currently striving to improve the accuracy of this assessment method.

Keywords: Esophageal cancer; metabolic tumor volume; neoadjuvant chemotherapy; positron emission tomography.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / radiotherapy*
  • Female
  • Fluorodeoxyglucose F18 / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neoplasm Staging
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Treatment Outcome

Substances

  • Fluorodeoxyglucose F18